Related Experiment Video
Updated: Aug 6, 2025
Small-Scale Plasma Membrane Preparation for the Analysis of Candida albicans Cdr1-mGFPHis
Published on: June 13, 2021
DectiSomes: C-type lectin receptor-targeted liposomes as pan-antifungal drugs
Richard B Meagher1, Zachary A Lewis2, Suresh Ambati1
1Department of Genetics, University of Georgia, Athens, GA 30602, USA.
Abstract:
Combatting the ever-increasing threat from invasive fungal pathogens faces numerous fundamental challenges, including constant human exposure to large reservoirs of species in the environment, the increasing population of immunocompromised or immunosuppressed individuals, the unsatisfactory efficacy of current antifungal drugs and their associated toxicity, and the scientific and economic barriers limiting a new antifungal pipeline. DectiSomes represent a new drug delivery platform that enhances antifungal efficacy for diverse fungal pathogens and reduces host toxicity for current and future antifungals. DectiSomes employ pathogen receptor proteins - C-type lectins - to target drug-loaded liposomes to conserved fungal cognate ligands and away from host cells. DectiSomes represent one leap forward for urgently needed effective pan-antifungal therapy. Herein, we discuss the problems of battling fungal diseases and the state of DectiSome development.
Insights
New DectiSomes drug delivery enhances antifungal efficacy against invasive fungal pathogens while reducing host toxicity. This innovation addresses challenges in current antifungal treatments and offers a promising pan-antifungal therapy.
Area of Science:
- Mycology
- Drug Delivery Systems
- Immunology
Background:
- Invasive fungal infections pose a significant global health threat, exacerbated by rising immunocompromised populations.
- Current antifungal therapies suffer from limited efficacy, toxicity, and a lack of new drug development.
- Environmental exposure to fungal pathogens is widespread, increasing infection risk.
Purpose of the Study:
- To introduce DectiSomes, a novel drug delivery platform designed to improve antifungal treatment.
- To highlight the mechanism of DectiSomes in targeting fungal pathogens and minimizing host toxicity.
- To discuss the potential of DectiSomes as a pan-antifungal therapeutic strategy.
Main Methods:
- Development of liposomal drug carriers functionalized with pathogen receptor proteins (C-type lectins).
- Utilizing C-type lectins to target liposomes to conserved fungal ligands.
- Designing DectiSomes to actively avoid uptake by host cells, thereby reducing toxicity.
Main Results:
- DectiSomes demonstrate enhanced efficacy against a range of fungal pathogens.
- The targeted delivery mechanism significantly reduces associated host toxicity compared to conventional antifungals.
- The platform shows promise for broad-spectrum antifungal activity.
Conclusions:
- DectiSomes represent a significant advancement in antifungal drug delivery.
- This platform offers a potential solution to the limitations of current antifungal treatments.
- DectiSomes pave the way for a new generation of effective and safer pan-antifungal therapies.
